Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

The receptor tyrosine kinase HER2 acts as oncogenic driver in numerous cancers. Usually, the gene is amplified, resulting in receptor overexpression, massively increased signaling and unchecked proliferation. However, tumors become frequently addicted to oncogenes and hence are druggable by targeted...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Kast, Florian, Schwill, Martin, Stüber, Jakob C., Pfundstein, Svende, Nagy-Davidescu, Gabriela, Rodríguez, Josep M. Monné, Seehusen, Frauke, Richter, Christian P., Honegger, Annemarie, Hartmann, Karen Patricia, Weber, Thomas G., Kroener, Felix, Ernst, Patrick, Piehler, Jacob, Plückthun, Andreas
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8213836/
https://ncbi.nlm.nih.gov/pubmed/34145240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-23948-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars